Alugen

Quick links to important sections

Alugen

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alugen

Property Description
Active ingredient Alfuzosin hydrochloride
Form Extended-release tablet (Oral)
Pharmacological class Selective Alpha-Blocker (α1-Antagonist)
General purpose Relieves tension in the urinary tract muscles
Origin Synthetic (Quinazoline derivative)

Defining Alugen: Active Ingredient and Formulation Type

Alugen is a specific pharmaceutical brand containing the active substance Alfuzosin hydrochloride. This compound is a chemically synthesized quinazoline derivative. A key feature of this medication is its presentation as an oral extended-release tablet, a design recognized for providing sustained pharmacological activity. This controlled delivery ensures the Alfuzosin is released slowly over time, aiming to maintain a consistent therapeutic effect throughout the day.


Alugen's Pharmacological Class and Unique Action

Alugen is classified as a selective alpha-blocker (α1-adrenergic antagonist), which works by inhibiting specific alpha-1 adrenoceptors. This action is clinically recognized for inducing smooth muscle relaxation. The active ingredient, Alfuzosin, is distinguished by its uroselectivity, meaning it preferentially targets the alpha-receptors located in the prostate and the bladder neck. This targeted action focuses the drug’s primary effect on the urinary tract structures rather than causing broader systemic effects.


General Purpose: Relieving Urinary Tract Tension

The essential purpose of Alugen's pharmacological action is to reduce resistance and facilitate urine flow in the lower urinary tract. By selectively relaxing the smooth muscle fibers that can restrict flow, the medication helps to relieve tension and obstruction. This core function is typically intended to improve urinary passage and promote more effective bladder emptying.

What side effects are possible with Alugen?

Possible side effects and safety information

Alugen's safety profile is officially documented by regulatory authorities, classifying possible adverse reactions by frequency and physiological system. This structure provides a factual framework for understanding the medicine’s established risk profile.


Adverse Reaction Scope

The most frequently classified reactions typically involve the Nervous System (e.g., dizziness, headache, asthenia/fatigue) and the Vascular System (e.g., postural hypotension). These effects, including dizziness and postural hypotension, are officially noted as being Common and are often more likely to occur at the start of treatment.

Frequency Classification Examples (SOC)
Common (1/100 to < 1/10) Dizziness, Headache, Postural Hypotension, Nausea
Uncommon (1/1,000 to < 1/100) Syncope (Fainting), Palpitations, Vertigo, Diarrhoea

Serious Adverse Reactions and Restrictions

Specific serious adverse reactions highlighted in official warnings include Priapism (a prolonged, painful erection) and Intraoperative Floppy Iris Syndrome (IFIS), a complication reported during cataract surgery in patients currently or previously exposed to alpha-blockers. Post-marketing reports also include cases of Hepatocellular Injury and Cholestatic Liver Disease.

Use of Alugen is formally contraindicated in patients with severe hepatic impairment (liver function problems) and in those with a history of orthostatic hypotension (a drop in blood pressure upon standing). Additionally, its use is prohibited alongside other alpha-1 receptor blocking agents.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Alfuzosin hydrochloride (Alugen) overdose emphasizes manifestations related to its pharmacological class. The primary clinical sign of an overdose is hypotension (low blood pressure), which may be severe or profound. This can lead to associated symptoms such as syncope (fainting), dizziness, and compensatory tachycardia (increased heart rate).

Immediate medical assistance is required for severe symptoms. Regulators mandate that emergency services must be contacted if an overdose results in a seizure, collapse, trouble breathing, or if the patient cannot be awakened. Additionally, a persistent and painful erection (priapism) lasting longer than four hours requires immediate medical help to prevent permanent damage. All suspected overdose cases warrant contacting a Poison Control Center and subsequent hospitalization for monitoring.

Official Supportive Measures

Management procedures described in regulatory labeling include placing the individual in the supine position and administering intravenous fluids to help restore blood pressure. If hypotension persists, the use of vasopressors may be necessary. It is officially stated that no specific antidote is known, and due to the drug's high protein binding, dialysis is likely not of benefit. Special consideration is noted for the elderly and patients with pre-existing cardiac conditions, who may face a greater risk of pronounced hypotension.

Therapeutic Uses of Alugen

What Alugen Treats: Main Uses and Benefits

Alugen is used in situations involving certain distressing symptoms. It is relevant in contexts marked by increased discomfort or tension where additional symptomatic support is needed.


Managing Acute Symptomatic Discomfort

The medication is commonly used to help with symptoms related to physical discomfort and symptoms related to heightened physiological activity. Relevant in clinical settings marked by increased discomfort or tension, this category of treatment is commonly used for symptoms like heartburn, acid indigestion, and sour stomach. It helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.


Addressing Episodic and Fluctuating Symptom Patterns

Alugen is considered relevant for easing symptoms associated with acute or episodic changes and conditions involving episodic or fluctuating manifestations. It is commonly used across conditions characterized by periods of heightened symptoms and offers symptomatic relief that helps patients cope more steadily with difficult, temporary episodes, supporting general well-being.


Support for Functional Strain and Daily Stability

Applied when symptoms create noticeable functional strain, Alugen provides support that helps ease the overall symptom burden. It is relevant for easing symptoms that interfere with daily comfort, offering supportive relief when they become temporarily overwhelming.

Quick Fact: Supports well-being during symptomatic phases (Assists with maintaining functional stability when symptoms become more noticeable.)

Regulatory References

  1. Aluminum Hydroxide and Magnesium Hydroxide: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Alugen (Alfuzosin hydrochloride) is officially indicated for use only in adult male patients and is not approved for use in the pediatric population. Safety and efficacy in children and adolescents have not been established.


Contraindicated Populations

Regulatory documentation strictly prohibits the use of Alugen in several patient groups:

  • Patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C).
  • Patients with known hypersensitivity to alfuzosin or any component of the tablet.
  • Patients who have a history of orthostatic hypotension.
  • Patients currently taking other alpha-1 receptor blocking agents or potent CYP3A4 inhibitors (such as ketoconazole or ritonavir).

Restricted and Conditional Use

Use is subject to caution or conditional limitation in other specific circumstances:

  • Severe renal impairment (creatinine clearance < 30 mL/min) requires caution, and use is not recommended by some authorities due to limited safety data.
  • Patients with mild hepatic impairment also require caution.
  • Caution is advised for patients with congenital or acquired QT prolongation or those with acute cardiac failure. Discontinuation is required if new or worsening angina pectoris symptoms appear.

What should I know about interactions with other medicines?

The interaction profile of Alugen (Alfuzosin) is structured around its clearance via the CYP3A4 metabolic enzyme and its class-specific alpha-adrenergic blocking effect. These domains establish specific regulatory restrictions for co-administration.


Contraindicated Combinations

Co-administration with potent CYP3A4 inhibitors (such as ketoconazole, itraconazole, and ritonavir) is formally contraindicated. This pharmacokinetic interaction results in a significant increase in alfuzosin plasma exposure (Cmax and AUC). Alugen is also contraindicated with other alpha-blockers due to the potential for an additive pharmacodynamic effect, which increases the risk of symptomatic hypotension.


Exposure and Pharmacodynamic Effects

Caution is advised when Alugen is co-administered with antihypertensive medications or nitrates due to potential additive blood pressure-lowering effects. Similarly, combining it with PDE5 inhibitors (e.g., sildenafil) requires caution. Moderate CYP3A4 inhibitors (e.g., diltiazem, cimetidine) are documented to increase alfuzosin exposure and require evaluation.


Population and Administration Constraints

A mandatory timing-based rule is documented, requiring the extended-release tablet to be taken with food and consistently with the same meal each day for correct absorption. Furthermore, use is officially contraindicated in patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C) due to the resulting significant increase in alfuzosin plasma concentrations in this population.

Mechanism of Action

Selective α₁-Adrenoceptor Blockade

Alugen (Alfuzosin) operates by acting as a selective competitive antagonist at post-synaptic α₁-adrenoceptors, which are highly expressed on the smooth muscle cells of the prostate and bladder neck. This interaction prevents the binding of the sympathetic neurotransmitter, norepinephrine, interrupting the signaling cascade responsible for initiating smooth muscle contraction.


Interruption of the Contraction Cascade

By blocking the receptor, the drug interrupts the associated G-protein signaling that triggers the release of intracellular calcium ions (Ca²⁺), which are essential for muscle contraction. This specific inhibition results in a local physiological effect known as myorelaxation. The functional consequence of this mechanism is concentrated in the lower urinary tract smooth muscle, a property referred to as functional uroselectivity.


Reduction of Dynamic Outflow Resistance

The resulting smooth muscle relaxation causes a decrease in the mechanical resistance within the infravesical (bladder outlet) structures. This physiological change lowers the urethral resistance and modifies the pressure-flow relationship within the lower urinary system. The mechanism only addresses the dynamic (tension-related) component of outflow resistance; it does not impact the static (anatomical) size of the tissue.

Dosage and Administration Information

Alugen is an extended-release tablet containing 10 mg of Alfuzosin hydrochloride, and its administration is governed by specific instructions to ensure proper release of the active substance. The administration route is oral, with the standard adult regimen being a 10 mg tablet taken once daily. To facilitate correct absorption, the medication must be taken immediately after the same meal each day.

Procedural Constraints

Instruction Type Requirement
Tablet Handling The 10 mg extended-release tablet must be swallowed whole and should not be chewed, crushed, or divided.
Missed Dose Rule If a dose is missed, the next dose should be taken as scheduled; do not take two doses to compensate for the missed tablet.

Duration and Population-Specific Patterns

The usage pattern often involves long-term daily administration for the primary indication. However, a specific short-term course of 3 – 4 days is documented for use in acute, specific clinical episodes.

Population Use Principles: Dosing adjustments are guided by functional status, not age alone. For older adults (65 years), the 10 mg once-daily dose is generally maintained. Caution is advised for patients with severe renal impairment (creatinine clearance < 30 mL/min). Furthermore, use is not indicated for the pediatric population and is contraindicated in patients with moderate or severe hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alugen


Evidence for Lower Urinary Tract Symptoms (LUTS) Suggestive of BPH

Research exploring how symptoms change over time in men with Benign Prostatic Hyperplasia (BPH) primarily relies on short-term, randomized controlled trials (RCTs). These are applied in studies examining patient-reported experiences for a defined period, allowing researchers to study patterns related to outcomes reflecting daily functioning or activity level. Studies report how symptoms evolved in the observed populations, alongside changes measured during the study period for objective measures of urine flow. Research also monitored outcomes related to functional imbalance, helping to contextualize how patients reported their experience during the study period. What remains uncertain is the full picture regarding the durability of these patterns over extended timeframes, as definitive comparative data is limited to the short-term. Long-term outcomes are not fully established, as information related to sustained changes over several years primarily comes from open-label studies.


Evidence for Acute Urinary Retention (AUR) Associated with BPH

Alugen was studied for Acute Urinary Retention (AUR) related to BPH in dedicated research studies conducted during periods of increased symptom activity. These trials studied research scenarios where symptoms become more noticeable, focusing on outcomes describing episodic or acute changes. Studies monitored the proportion of participants achieving spontaneous voiding when a temporary catheter was removed—a process known as a Trial Without Catheter (TWOC). Research also monitored outcomes related to functional imbalance, such as the frequency with which patients required re-catheterization or surgery during the months following the acute episode. Follow-up durations were limited in some of the studies examining how patients fared after the TWOC event. Consequently, evidence derived from settings with varying symptom burdens for preventing long-term recurrence remains limited.


Research on Long-Term Outcomes and Follow-up

Research examined long-term outcomes for conditions characterized by fluctuating or episodic manifestations, utilizing open-label extension studies and long-term observational cohorts. However, there is limited information for long-term outcomes because the gold standard of placebo-controlled research typically extends for only a few months. Long-term data often comes from studies where the treatment was known to the participants and researchers, and therefore the certainty of the findings is less established than in double-blind trials. Fewer data are available because of the specific patient inclusion criteria that were used in the trials.

Key Studies & References

  1. Alfuzosin 10 mg prolonged-release tablets - Public Assessment Report (Regulatory Context)

Frequently Asked Questions (FAQ)

Common questions about Alugen (FAQ)

Q: Is Alugen the same type of medicine as Pepto-Bismol or Tums?

No, Alugen is chemically different from these products. Official product information states that Alugen (Alfuzosin) is classified as an alpha-1 adrenergic antagonist, which works to relax certain muscles in the urinary tract. Medicines like Pepto-Bismol or Tums are antacids or similar agents used for relief from gastrointestinal symptoms like heartburn or upset stomach.

Q: What is the difference between an antacid like Alugen and a PPI (Proton Pump Inhibitor)?

Alugen is not an antacid or a PPI. It is an alpha-1 adrenergic antagonist that acts on muscles in the lower urinary tract to improve urine flow. Antacids and PPIs, by contrast, are drug classes specifically designed to work in the stomach by neutralizing or reducing the amount of acid produced.

Q: Are there any specific foods or drinks to avoid while taking Alugen?

Regulatory documents state that the tablet should be taken immediately after the same meal each day. This consistent timing is important for the medicine’s expected effect. Additionally, official information advises caution regarding alcohol consumption, as it may increase the risk of side effects like dizziness and low blood pressure.

Q: What signs indicate that Alugen might be causing constipation?

Constipation is listed among the possible side effects associated with Alugen (alfuzosin), according to official safety information. Difficulty passing stools or infrequent bowel movements are common ways this side effect may manifest, according to safety reports.

Q: How long can a person take Alugen safely before needing a break?

Alugen is primarily indicated for long-term daily administration for the chronic management of symptoms. The official regulatory label does not specify a maximum time after which a patient must stop or take a break from the medication.

Q: Does Alugen interact with any common blood pressure medications?

Yes, caution is advised if Alugen is co-administered with antihypertensive medications (for high blood pressure) or nitrates. Combining these medicines has been observed to carry the potential for an additive effect, which may increase the risk of low blood pressure (hypotension).

Q: Is it possible for Alugen to change the color of stools?

Official post-marketing reports for the active ingredient (Alfuzosin) include cases of clay-colored stools or dark urine. Regulatory reports note that such changes may occur and are sometimes linked to more serious, yet rare, adverse reactions.

Q: Does Alugen lose its effectiveness if taken with a large amount of water?

The extended-release tablet must be swallowed whole and taken right after a meal to ensure the medicine is released correctly over time. Regulatory documents do not address the specific volume of water, but it is important that the specific administration rules are followed as directed, to help maintain the drug's intended effectiveness.

Q: Are there any long-term health concerns associated with taking Alugen regularly?

Official safety warnings highlight specific risks associated with long-term use. These include the risk of Priapism (a prolonged, painful erection) and the development of Intraoperative Floppy Iris Syndrome (IFIS), which is a complication reported during cataract surgery in patients using alpha-blockers.

Q: Does Alugen interact with any herbal supplements, like St. John's Wort?

Alugen is processed by the body through an enzyme called CYP3A4. Therefore, products that strongly inhibit this enzyme are contraindicated (prohibited). Caution is generally advised regarding supplements known to affect CYP3A4 activity.

Q: Is Alugen a systemic medicine, or does it only work in the digestive tract?

Alugen is a systemic medicine. The drug is absorbed from the digestive tract and enters the bloodstream to be distributed throughout the body. Its effect is concentrated in the lower urinary tract, but its pharmacological action is systemic.

Q: What common prescription drugs are known to have moderate or minor interactions with Alugen?

Official information lists specific drugs that require caution, such as the moderate CYP3A4 inhibitors like Diltiazem and the H2-blocker Cimetidine. Combining Alugen with PDE5 inhibitors (like sildenafil) also requires caution due to the potential for blood pressure effects.

Q: What is the typical timeframe for Alugen's peak effect after taking it?

Pharmacokinetic studies show that the drug generally reaches its maximum concentration in the blood (known as Cmax) about eight hours after the extended-release tablet is taken with a meal. This peak is part of the drug’s intended slow and sustained release.

Q: What does the research say about the safety of Alugen's aluminum content?

This question is based on a misunderstanding of the drug's composition. Alugen's active ingredient is Alfuzosin hydrochloride, a synthetic compound. The official regulatory description of the drug does not list aluminum as an active or primary inactive ingredient.

Q: Does Alugen interact with birth control pills?

Regulatory labels do not explicitly mention birth control pills, but caution is advised with hormonal contraceptives that contain ethinyl estradiol and progestin combinations. This is because such combinations can potentially interact with the CYP3A4 enzyme pathway that processes Alugen in the body.

Q: Are the warnings about Alugen and other medications minor or major concerns?

Regulatory documents classify interactions into different levels of concern. These range from Contraindicated (which means the combination is prohibited) to Warning (indicating a significant known risk like hypotension or syncope) to Caution (meaning the combination requires monitoring for increased effects), depending on the specific drug.

Q: What are the potential differences in effect between the liquid and tablet forms of Alugen?

Alugen is only approved and supplied as a 10 mg extended-release tablet. The drug is not available in an official liquid or suspension form for administration, as its function relies on the slow release provided by the tablet formulation.

Q: What are the general guidelines for using Alugen only 'as needed'?

Official dosing guidelines state that Alugen is approved to be taken as a single tablet once daily. The medication is not indicated or approved for use on an 'as needed' basis, as its sustained-release design is intended for daily dosing.

Q: What research supports using Alugen to treat conditions other than BPH?

The official approved uses for Alugen are specifically limited. The drug is indicated for the treatment of Lower Urinary Tract Symptoms (LUTS) suggestive of BPH and the management of Acute Urinary Retention (AUR) associated with BPH. Its use for other conditions is not supported by the official indications.

Q: Is Alugen the same as Tamsulosin, Silodosin, or other Alpha-Blockers?

Alugen (Alfuzosin) is a distinct medication from Tamsulosin or Silodosin. However, all three belong to the class of alpha-1 receptor blocking agents. Co-administration with other medicines from this same class is contraindicated (prohibited) due to the high risk of severe low blood pressure.

Q: Can Alugen be taken by people who are pregnant or breastfeeding?

Alugen is officially indicated for use only in adult male patients. Its safety and effectiveness have not been established in female patients, and the official label does not support its use in women who are pregnant or breastfeeding.

Q: Is the sensation of nausea a common side effect when starting Alugen?

Yes, nausea is classified as a Common side effect in official safety reports. Furthermore, common effects like dizziness and low blood pressure are noted as being more likely to occur when you first begin taking the treatment.

Q: What should be done if Alugen accidentally freezes?

Alugen must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Temperatures outside this controlled range, including freezing, are not recommended and may potentially affect the drug's properties and make it unsuitable for use.

Q: Can Alugen be taken if a person has difficulty swallowing?

No. The extended-release tablet must be swallowed whole. Official instructions state that it is necessary not to chew, crush, or divide the tablet, as doing so would interfere with the controlled-release mechanism of the drug.

Q: Does Alugen affect driving or operating machinery?

Adverse reactions such as dizziness, vertigo (a sensation of spinning), and asthenia (fatigue) are common, especially when starting treatment. Because of these potential effects, the official guidance states that patients should avoid activities such as driving or operating machinery until they have established how the medication affects them.

Q: Is it normal to experience dizziness when taking Alugen?

Yes, dizziness is classified as a Common side effect, meaning it is one of the more frequently observed effects documented in clinical trials. It is a known effect of the drug’s mechanism of action, which involves blocking certain nerve receptors.

How should Alugen be stored and disposed of?

How to Store and Dispose of Alugen

The storage and disposal instructions for Alugen (Alfuzosin hydrochloride extended-release tablets) are essential for maintaining the product's quality and ensuring safety, as defined by regulatory documents.


Official Storage Requirements

Alugen must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with permitted temperature excursions up to 30 C (86 F). The medication requires protection from light and excess moisture and must be kept in its original container with the cap tightly closed.


Disposal and Child Safety

This medicine must be stored out of the reach of children. Unused or expired Alugen tablets must not be disposed of by flushing them down a toilet or pouring them into a drain (wastewater). Disposal must follow specific local requirements for pharmaceutical waste, such as official drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alugen found in:

A-Z Index: